A detailed history of Larson Financial Group LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Larson Financial Group LLC holds 244 shares of EDIT stock, worth $326. This represents 0.0% of its overall portfolio holdings.

Number of Shares
244
Previous 244 -0.0%
Holding current value
$326
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 02, 2024

SELL
$4.67 - $7.28 $2,335 - $3,640
-500 Reduced 67.2%
244 $1,000
Q1 2024

May 03, 2024

BUY
$7.03 - $11.07 $3,515 - $5,535
500 Added 204.92%
744 $5,000
Q1 2021

May 06, 2021

BUY
$39.71 - $90.58 $3,971 - $9,058
100 Added 69.44%
244 $10,000
Q3 2020

Oct 08, 2020

BUY
$28.06 - $37.16 $4,040 - $5,351
144 New
144 $4,000
Q1 2020

Apr 09, 2020

SELL
$14.88 - $32.78 $7,440 - $16,390
-500 Closed
0 $0
Q4 2019

Jan 10, 2020

BUY
$19.49 - $32.63 $9,745 - $16,315
500 New
500 $15,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $92.1M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Larson Financial Group LLC Portfolio

Follow Larson Financial Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Larson Financial Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Larson Financial Group LLC with notifications on news.